Matinas: Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in Melanoma Model

 Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Currently, docetaxel is administered intravenously and can be associated with significant side effects and toxicities.

https://finance.yahoo.com/news/matinas-biopharma-announces-positive-vivo-123000703.html